Underpowered or negative? A crucial distinction
- 296 Downloads
KeywordsClinical trial Human Hyperinsulinaemic–euglycaemic clamp Insulin sensitivity NAD+ metabolism Nicotinamide riboside
All authors were responsible for drafting the article and revising it critically for important intellectual content. All authors approved the version to be published.
Duality of interest
The authors declare that there is no duality of interest associated with this manuscript.
- 1.Connell NJ, Houtkooper RH, Schrauwen P (2019) NAD+ metabolism as a target for metabolic health: have we found the silver bullet? Diabetologia. https://doi.org/10.1007/s00125-019-4831-3
- 2.Dollerup OL, Christensen B, Svart M et al (2018) A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. Am J Clin Nutr 108(2):343–353. https://doi.org/10.1093/ajcn/nqy132 CrossRefPubMedPubMedCentralGoogle Scholar
- 4.Malin SK, Haus JM, Solomon TPJ et al (2013) Insulin sensitivity and metabolic flexibility following exercise training among different obese insulin-resistant phenotypes. Am J Physiol Endocrinol Metab 305(10):E1292–E1298. https://doi.org/10.1152/ajpendo.00441.2013 CrossRefPubMedPubMedCentralGoogle Scholar